The research was published on Chemical Biology & Drug Design. The MYC protein is a well-established driver in up to 70% of human cancers, but has long been considered “undruggable” due to the ...

MYC is dysregulated in nearly 70% of human cancers, where it influences a vast network of biological processes including cell cycle control, metabolism, apoptosis, angiogenesis, and immune evasion.

Pioneered by Dr. Chidiebere Awah MD, PhD, our CEO and Principal Investigator, UTRxM1-18 targets oncogenic c-MYC by recognizing specific motifs and switching the ribosome machinery from a ...

Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail the growth of several cancer types. A review paper published last year in European ...

MANILA, Philippines — The Balikatan sa Kaunlaran (BSK) National Foundation, a 48-year-old non-government organization that aims to empower Filipino entrepreneurs, will launch the “Philippine M ...

BSK has a proven track record of building and scaling brands in the U.S. market which will allow Xebra to tap into an established network and infrastructure. BSK's proven online sales ecosystem ...

The wholly owned MRT-2359 is Monte Rosa’s attempt to exploit a vulnerability of MYC-driven tumors. Believing the tumors are dependent on GSPT1, the biotech designed a molecule to drive ...

This partnership aims to expand Elements branded CBD products to the Mexican market through a robust e-commerce platform, leveraging BSK's extensive track record and success in the CBD and hemp ...

In healthy cells, a protein called MYC helps guide the process of transcription, in which genetic information is converted from DNA into RNA. But when cells turn cancerous, they start to produce way ...

Study: MYC-Targeting Inhibitors Generated from a Stereodiversified Bicyclic Peptide Library. Image Credit: Christoph Burgstedt / Shutterstock.com MYC, a transcription factor involved in most human ...